A
A-Alpha Bio
Provider of cell-based tools for quantitative and high-throughput measurements of protein interactions
About A-Alpha Bio
AalphaBio operates in the biotechnology sector, focusing on the discovery and optimization of biologics, which are therapeutic proteins used to treat diseases. The company serves pharmaceutical and biotech firms looking to develop new drugs with high specificity and efficacy. AalphaBio's core business model revolves around its proprietary platform that can rapidly and quantitatively measure millions of protein-protein binding affinities, allowing for the characterization of library binding to many targets simultaneously. This platform is particularly useful for screening antagonists against full interaction networks and discovering biologics with defined specificity to multiple targets. The company generates revenue through service contracts, licensing agreements, and collaborative partnerships with other biotech and pharmaceutical companies. AalphaBio has been recognized as one of the 50 digital tech companies poised for greatness and has received a National Science Foundation SBIR grant to further develop its technology.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Seattle, United States
- Employees
- 51
- Open positions
- None listed
- Dealroom signal
- 65.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Synthetic Biology, Spinout, Tech for Biotech and Pharma, Generative AI, AI Drug Discovery
- Technology
- Artificial Intelligence, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | May 2024 | $15M | — | US Department of War | ↗ |
| SERIES AOther financing | Jul 2023 | $22M | $90M | Madrona Venture Group · Perceptive Advisors · Breakout Ventures | ↗ |
Growth signals
Latest recorded traffic for A-Alpha Bio is 8.1K monthly website visits, up 102.5% over the last three months. A-Alpha Bio's team declined 1.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
US National Science Foundation
OS Fund
AME Cloud Ventures
Madrona Venture Group
US Department of War
Series A3 investors entered at this stage
Lux Capital
Perceptive Advisors
Breakout Ventures
Other known investors1 additional known investor
University of Washington
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about A-Alpha Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See A-Alpha Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.